Here’s what you should know.
1. The guidance is designed to address how the CFDA will address 3-D printed devices on the Chinese market.
2. The scope of the guidance covers implantable devices for orthopedics and dental. It also references biomaterials and pharmaceuticals produced using additive manufacturing.
3. CFDA is requiring validation testing for 3-D printed manufacturing equipment and processes. It’s also testing materials, software and final products.
4. According to the CFDA, environmental parameters for additive manufacturing should be defined to include temperature, pressure, humidity, gas composition, printing speed, energy density and other related factors.
For more information on the approval process, click here.
https://www.emergogroup.com/blog/2018/03/new-guidance-china-fda-3d-printed-medical-device-registration-rules-0
More articles on supply chain:
UnitedHealth takes aim at Envision’s ER billing practices through new website — 5 insights
Muve Health plans expansion to 30 facilities, plus 4 key quotes from CEO P. Marshall Maran
Wills Eye appeals to change classification from ASC to hospital: 4 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.